Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
AL

OTC · ALPMY

Astellas Pharma Inc.

Healthcare · Drug Manufacturers - General

$14.35

Up+$0.15 (+1.06%)

Updated Oct 11, 2026, 10:29 PM

SID Score

6.5/10

Composite research score

Smart Money

46/100

Neutral

Market cap
29.58B
P/E ratio
14.43
Dividend yield
3.36%
52-week range
— – —
Volume
9.17K
Avg. volume
127.41K

Price performance · ALPMY

ALPMY price history

1M range · 0 trading sessions · Daily adjusted prices

ALPMY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ALPMY news

The latest Smart Investors Daily articles mentioning ALPMY.

Stock researchCompany · Overview

ALPMY research

Overview

Company profile and research snapshot.

Company profile

ASTELLAS PHARMA UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

SAN FRANCISCO, October 08, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC). VIR-5500 is being co-developed by Astellas Pharma Inc. and Vir Biotechnology through a global strategic collaboration.

Yahoo · Oct 6, 2026

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that 21 abstracts from its oncology portfolio will be presented at the European Society for Medical Oncology Congress 2026 (ESMO 2026), taking place October 23–27 in Madrid, Spain. The presentations span prostate, urothelial, gastric/gastroesophageal junction (GEJ), lung and pancreatic cancers, reflecting Astellas' commitment to advancing standards of care and pursuing new scientific approaches designe

Yahoo · Oct 2, 2026

New Preliminary Real-World VEOZAH™ (fezolinetant) Data Highlights Improvements in Menopause-Related Symptoms and Sleep Outcomes

Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") presented a new preliminary analysis from the Phase 4 OPTION-VMS real-world study of non-hormonal therapies (non-HTs) for bothersome vasomotor symptoms (VMS, also known as hot flashes and night sweats) at the 2026 International Menopause Society (IMS) 20th World Congress on Menopause. The analysis showed that VEOZAH (fezolinetant 45mg) treatment was associated with statistically significant improvements from baseline

Yahoo · Sep 29, 2026

Astellas Pharma Inc's Dividend Analysis

This article first appeared on GuruFocus. Astellas Pharma Inc (ALPMF) recently announced a total dividend of $0.25 per share, with the ex-dividend date set for 2026-09-29. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By